Elderly patients (age > 75) sustain larger infarcts with greater mortality from ST elevation myocardial infarcts (STEMI) despite successful reperfusion treatment. Elderly age remains an independent risk despite correction for clinical and angiographic variables. The elderly represent a high-risk population and may benefit from treatment in addition to reperfusion alone. We hypothesized that modulation of cardiac signaling and metabolism with acute, high dose metformin given at reperfusion would exhibit additional cardioprotection. Using a translational aging murine model (22-24-month C57BL/6J mice) of in vivo STEMI (45 min artery occlusion with reperfusion for 24 hours); treatment acutely at reperfusion by high dose metformin decreased infarct size and enhanced contractile recovery, demonstrating cardioprotection in the high-risk aging heart.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529738PMC
http://dx.doi.org/10.14336/AD.2023.0205DOI Listing

Publication Analysis

Top Keywords

high dose
12
dose metformin
12
acute high
8
infarct size
8
high-risk aging
8
aging heart
8
reperfusion
6
metformin therapy
4
therapy reperfusion
4
reperfusion decreases
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!